Cheaper hormone treatment recommended for cancer, endometriosis and gender care

Government advisers want a hormone drug called triptorelin added to the PBS — the scheme that makes medicines cheaper. It covers breast cancer, endometriosis and gender dysphoria. A rival drug's withdrawal left 7,500-plus cancer patients at risk. If approved, gender-affirming care hits the PBS for the first time, dropping yearly costs from about $3,000 to roughly $300.